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Treating anemia early in renal failure patients slows the decline
of renal function: A randomized controlled trial.
Background. Erythropoietin is known to improve outcomes
in patients with anemia from chronic renal disease. However,
there is uncertainty about the optimal timing of initiation of
erythropoietin treatment in predialysis patients with non-severe
anemia.
Methods. We conducted a randomized controlled trial of
early versus deferred initiation of erythropoietin in nondiabetic
predialysis patients with serum creatinine 2 to 6 mg/dL and
hemoglobin 9 to 11.6 g/dL. The early treatment arm was im-
mediately started on 50 U/kg/wk of erythropoietin alpha with
appropriate titration aiming for hemoglobin of ≥13 g/dL. The
deferred treatment arm would start erythropoietin only when
hemoglobin decreased to <9 g/dL. The primary end point was
a composite of doubling of creatinine, renal replacement, or
death.
Results. Eighty-eight patients were randomized (early treat-
ment N = 45, deferred treatment N = 43) and followed for a
median of 22.5 months. During follow-up, 13 versus 23 patients
reached the primary end point in the two arms, respectively (log-
rank P = 0.0078). The relative hazard for reaching an end point
was 0.42 (P = 0.012). Adjusting for baseline serum creatinine,
the adjusted relative hazard was 0.37 (P = 0.004), while the risk
increased 2.23-fold (P < 0.001) per 1 mg/dL higher creatinine
at baseline. The benefit was similar regardless of the baseline
hemoglobin and proteinuria. No patients had any severe ad-
verse events.
Conclusion. Early initiation of erythropoietin in predialysis
patients with non-severe anemia significantly slows the progres-
sion of renal disease and delays the initiation of renal replace-
ment therapy.
Erythropoietin (EPO) administration can correct the
anemia associated with renal failure in predialysis pa-
tients [1–9]. Early concerns [10] about a potential de-
terioration of renal function in EPO users have been
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abated by clinical evidence [4, 5, 7] showing that EPO
does not deteriorate renal function. Nevertheless, the use
of EPO in predialysis patients is more controversial in
patients where the anemia is not so prominent. The best
time to start treatment is uncertain. Usually, anemia pro-
gresses along with the deterioration of renal function,
but the correlation is not perfect. Guidelines have moved
the threshold for starting EPO treatment toward higher
hemoglobin levels (i.e., to recommend earlier treatment),
when the hemoglobin drops below 10 g/dL in the United
States guidelines [11, 12], and below 11 g/dL in the Euro-
pean guidelines [13]. Nevertheless, surveys show that the
use of EPO before dialysis is still uncommon in clinical
practice [14–16], and most patients dont start EPO until
the anemia is advanced. Patients without severe anemia
may not benefit much symptomatically from the correc-
tion of anemia, and the cost of the treatment along with
potential side effects may have to be considered more se-
riously. However, EPO would still be very useful in this
setting if it can slow renal disease progression and delay
the need for renal replacement.
In order to evaluate whether EPO can slow the pro-
gression of chronic disease in predialysis patients with
non-severe anemia, we undertook a randomized trial that
compared two strategies: immediate onset of treatment
versus deferring EPO treatment until the hemoglobin
dropped to below 9 g/dL.
METHODS
Eligibility criteria
Predialysis patients with renal impairment result-
ing from any cause other than diabetes mellitus with
screening serum creatinine values 2.0 to 6.0 mg/dL and
hemoglobin of 9.0 to 11.6 g/dL were eligible for the study.
Patients with hemoglobin less than 9 g/dL were consid-
ered as candidates for immediate onset of EPO treatment
and were not included in the trial. Other exclusion crite-
ria were the presence of an easily correctable cause of
anemia, such as iron deficiency (transferrin saturation
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<20%), transfusion dependency, the presence of sys-
temic diseases, infections, or inflammatory conditions
that might inhibit the effect of EPO, age <18 years
or >85 years, uncontrollable hypertension, proteinuria
>2 g per 24 hours, serum albumin <3.5 g/dL, hepatic
insufficiency, active hepatitis, uncontrollable hypothy-
roidism, chronic alcoholism, congestive heart failure
(New York Heart Association class III or IV), severe obe-
sity (body mass index >40 kg/m2), nPNA ≤0.8 g/kg/day,
history of seizures of thrombotic episodes, pregnancy, lac-
tation, known hypersensitivity to EPO alpha, use of an-
tilipidemic drugs, use of corticosteroids in the previous
6 months, and use of EPO in the previous 6 months. Be-
cause of concerns about induced EPO resistance at the
time the study was launched [17–19], patients receiving
angiotensin-converting enzyme inhibitors (ACEIs) or an-
giotensin II receptor blockers (ARBs) could participate if
they were willing to stop these drugs, and adequate blood
pressure control could be achieved with other drugs for
at least 2 months before proceeding with randomization.
Treatment allocation
Patients were randomized to two treatment arms. In
the early treatment arm patients were started immedi-
ately on subcutaneous EPO alpha (Eprex, Janssen-Cilag
Pharmaceutical, Athens, Greece) 50 U per kg once per
week. In the deferred treatment arm, EPO was initiated
only when the hemoglobin decreased during follow-up
to less than 9 g/dL (confirmed on a second measurement
within less than 1 week). Dose schedules and titration of
EPO was otherwise the same in the two arms. For patients
receiving EPO, it was recommended that there should be
no effort to further increase the hemoglobin once it had
exceeded 13 g/dL. For patients exceeding this target, the
dose of EPO was titrated downward to 25 U per kg once
per week, or it could remain the same, according to the
discretion of the clinician. For patients not reaching the
target of 13 g/dL, 25 U per kg dose increments were al-
lowed each month. Whenever the hemoglobin decreased
again to below 11.6 g/dL and there was no easily identifi-
able cause that could be corrected, it was recommended
that the dose of EPO should be titrated upwards by 25 U
per kg to again reach the appropriate hemoglobin range.
All centers followed common principles for the mon-
itoring of blood pressure, treatment of hypertension,
dietary instructions, and renal failure management. Mon-
itoring of blood pressure and treatment of hypertension
was performed according to established standards, aim-
ing for blood pressure levels <130/85 mm Hg [20] when-
ever possible, using restricted salt intake, and appropriate
drug therapy, at the discretion of the treating clinician.
For patients with higher blood pressures in the office set-
ting, we obtained 24-hour measurements for more accu-
rate monitoring. Hypertension was managed avoiding the
use of ACEIs and ARBs, to avoid potential EPO resis-
tance [17–19]. Protein intake was generally restricted to
less than 1 g/kg per day [21] based on appropriate dietary
instructions given to the patients. No extra-low protein
diets were employed in the study. Patients developing
iron deficiency with documented transferrin saturation
<20% were treated with oral iron supplementation. Two
patients who had intolerance to oral iron received intra-
venous iron supplementation.
Patients were randomized using a computerized se-
quence kept at the coordinating center at the University
of Ioannina. Once a patient had consented to be random-
ized, randomization was performed centrally.
End points
The study had two main end points. The first end point
was progression of renal disease (defined as doubling of
creatinine, a creatinine of >8 mg/dL, initiation of renal
replacement) or death from any cause. The second end
point was initiation of renal replacement or death from
any cause, whichever occurred first. We also examined
whether the level of renal failure was different in the two
arms at the time of initiating renal replacement for those
patients who started renal replacement.
Secondary end points included the levels of
hemoglobin and hematocrit, serum creatinine, and
creatinine clearance at 12 months. Creatinine clearance
was determined using the Cockroft-Gault formula.
As part of safety assessments, we recorded hospitaliza-
tions due to any reason, the occurrence of uncontrolled
hypertension, severe anemia (hemoglobin <7 g/dL), and
allergic local or systemic reactions. Comparisons of blood
pressure at 12 months between the two arms were made
adjusting for baseline measurements in analysis of vari-
ance. A nested substudy also collected information on
serum lipid parameters on selected patients (data not
shown).
Follow-up and measurements
Besides the screening measurements that were used
for justifying eligibility, patients also had separate base-
line measurements at the time of randomization. Pa-
tients were seen then on an outpatient basis at 2, 4, 6, 9,
12 months, and every 3 months thereafter. Additional
visits could be made in cases of acute medical problems.
At each study visit, vital signs and weight were recorded,
and measurements included complete blood cell count,
serum creatinine and urea, electrolytes, glucose, iron, fer-
ritin, total iron binding capacity, urinalysis, and 24-hour
urine protein, urea, and creatinine determinations.
Sample size calculations and protocol modification
The study was designed in order to have 80% power
to show with alpha = 0.05, a 50% reduction in the
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hazard of doubling of creatinine, creatinine >8 mg/dL,
renal replacement, or death during follow-up in the early
treatment arm versus the deferred treatment arm. With
these estimates, we aimed for capturing 66 events dur-
ing follow-up in the two arms combined. We expected
that with 2.5 years of follow-up, two thirds of the pa-
tients would have an event; thus, 100 randomized patients
would have to be followed for an average of 2.5 years.
We expected that approximately 50 patients could be re-
cruited rapidly, and another 50 would then be entered in
the trial over a period of approximately 12 months. Thus,
it was anticipated that the trial should continue until all
patients had completed 2 years of follow-up.
In February 2002, case series of pure red-cell aplasia
(PRCA) were reported in patients receiving mainly sub-
cutaneous EPO alpha [22]. Although no such adverse
events had been recorded in any of the enrolled patients
in our study, enrollment of new patients was suspended,
with 88% of the target enrollment being achieved. In
November 2002, the indication of subcutaneous EPO al-
pha administration in chronic renal failure patients was
withdrawn because PRCA had been documented in a fur-
ther number of patients receiving EPO (mainly subcuta-
neous EPO alpha) in Europe, Australia, and Canada [23].
At this point all study patients were informed of this mod-
ification and subcutaneous EPO alpha was discontinued.
Patients in both arms could then use an alternative form
of EPO (e.g., subcutaneous EPO beta or darbepoietin)
at the discretion of their physicians. It was felt that the
potential drop-in of patients between the two arms could
blur subsequent differences during prolonged follow-up
because the treatment experience of the two arms would
become relatively homogenized after this modification.
Thus, it was elected to terminate the study and analyze
the data at 1 year after the recruitment of the last patient.
Statistical analyses
All analyses are based on intention-to-treat with pa-
tients analyzed in the arm where they were originally
randomized. The primary end points were analyzed with
Kaplan-Meier curves using the log-rank test for compar-
ison and with proportional hazards models. Proportional
hazards models were also adjusted for age, sex, and base-
line hematologic parameters, serum creatinine, creatinine
clearance, and proteinuria. We also assessed whether the
results were different in subgroups defined by baseline
parameters. For secondary continuous outcomes, we used
analysis of variance (ANOVA), adjusting for baseline
measurements. In the case of missing values because of
death, loss to follow-up, or missed appointment, we used
the last observation carried forward approach; in partic-
ular, for serum creatinine and creatinine clearance, the
same approach was used to carry forward the last value
of creatinine before initiation of renal replacement, for
Table 1. Baseline characteristics
Deferred
Early arm arm
N = 45 N = 43 P valuea
Female/male 20/25 18/25 0.98
Age, mean (SD), years 66.7 (10.4) 64.2 (12.2) 0.44
Weight, mean (SD), kg 72.3 (8.9) 70.4 (9.4) 0.44
Hemoglobin, mean (SD), g/dL 10.1 (0.5) 10.1 (0.6) 0.72
Hematocrit, mean (SD), % 30.8 (1.4) 31.0 (1.1) 0.58
Serum creatinine, mean (SD), 3.27 (0.99) 3.39 (0.82) 0.27
mg/dL
Creatinine clearance, 25.7 (9.1) 22.3 (6.0) 0.14
mean (SD), mL/min
History of hypertension, N (%) 42 (93) 36 (84) 0.19
24-hour protein, mean (SD), g 0.66 (0.39) 0.57 (0.36) 0.28
aBased on Mann-Whitney U test and chi-square test with continuity correction,
as appropriate.
patients who initiated renal replacement. Comparisons
of discrete and continuous variables between groups at
baseline were performed using the chi-square test with
continuity correction and the t test, respectively.
Analyses were conducted with SPSS 11.0 (SPSS, Inc.,
Chicago, IL, USA). All P values are two-tailed.
Ethical issues
The study was approved by the hospital ethics board,
and all patients provided informed consent. The sponsor
had no role in the design of the study, in the collection,
analysis, or interpretation of the data, or the drafting of
the manuscript. The principal investigators had all the
data collected during this trial available, and were re-
sponsible for manuscript submission.
RESULTS
Trial population
A total of 88 patients were enrolled in the study across
14 participating hospitals in Greece between November
2000 and June 2002. Forty-five were randomized in the
early treatment arm and 43 were randomized in the de-
ferred treatment arm. Patients were followed for a me-
dian of 22.5 months (interquartile range 16 to 24 months)
and the total follow-up was 147.4 person-years. In the
early treatment arm, 3 patients died (prostate cancer,
cerebrovascular event, and car accident) and one was
lost to follow-up. In the deferred treatment arm, 4 pa-
tients died (ischemic heart disease N = 3, cerebrovascu-
lar disease) and 2 were lost to follow-up. In the early
treatment arm, patients spent a median of 17 months
(interquartile range 11 to 19) in the original EPO reg-
imen. In the deferred treatment arm, patients spent a
median of 12 months (interquartile range 7 to 18) with-
out any EPO. None of the patients in the deferred arm
had their hemoglobin fall below 9 g/dL during follow-
up. The two groups were well balanced in regards to
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Table 2. Hematologic and renal parameters at 12 months
Deferred
Early arm arm P valuea
Hemoglobin, mean (SD), g/dL 12.9 (0.4) 10.3 (1.0) <0.001
Hematocrit, mean (SD), % 38.4 (1.5) 31.4 (2.6) <0.001
Serum creatinine, mean (SD), 3.81 (1.43) 5.07 (2.39) <0.001
mg/dL
Creatinine clearance, mean (SD), 21.9 (9.4) 16.1 (6.3) <0.001
mL/min
aP values are based on analysis of covariance adjusting for the baseline values.
Last observation carried forward has been applied in the analyses, as described
in Methods.
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Fig. 1. Hemoglobin levels at baseline and during follow-up (at 2, 4, 6,
9, and 12 months) in the deferred (white boxes) and early (gray boxes)
treatment groups. The box plots show the median (horizontal line),
interquartile range (box), and range (whiskers), unless there are also
outliers and/or extreme values with 1.5 to 3 and >3 box lengths, respec-
tively, away from the edge of the box, in which case these are shown by
circles and asterisks.
all baseline characteristics (Table 1). The majority of pa-
tients had a history of hypertension, while 10 patients had
biopsy-documented glomerulonephritis (6 and 4 in the
two arms, respectively), 3 patients had polycystic disease
(1 and 2 in the two arms, respectively), and 3 had ob-
structive nephropathy caused by nephrolithiasis (1 and 2
in the two arms, respectively). The majority of patients
(30 and 35 patients in the early and deferred EPO arms,
respectively) had stage 4 chronic kidney disease, while a
few patients had stage 5 chronic kidney disease (5 and 3
in the two arms, respectively), or stage 3 disease (10 and
5 in the two arms, respectively).
Hematologic and renal function parameters at 12 months
At 12 months, the two groups clearly differed in lev-
els of hemoglobin and hematocrit (Table 2, Fig. 1). With
one exception, patients in the early treatment arm consis-
tently managed to reach hemoglobin levels of 12.5 mg/dL
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Fig. 2. Serum creatinine levels at baseline and during follow-up (at 2,
4, 6, 9, and 12 months) in the deferred (white boxes) and early (gray
boxes) treatment groups. The box plots show the median (horizontal
line), interquartile range (box), and range (whiskers), unless there are
also outliers and/or extreme values with 1.5 to 3 and >3 box lengths,
respectively, away from the edge of the box, in which case these are
shown by circles and asterisks. Not shown are two creatinine values
above 10 mg/dL.
or higher, while most patients on the deferred treatment
arm who had started EPO in the interim had also reached
similar hemoglobin levels. Serum creatinine and creati-
nine clearance were also significantly better in the early
treatment group than in the deferred treatment group
(Table 2, Fig. 2).
Primary end points for long-term follow-up
During follow-up, 13 versus 23 patients reached the
end point of doubling of creatinine, renal replacement, or
death in the early versus deferred treatment arms, respec-
tively. For renal replacement or death, there were 13 ver-
sus 22 patients with an event in the two arms, respectively.
In the early treatment arm, 3 patients died and 10 patients
started renal replacement (6 of whom had doubled their
serum creatinine or had reached values >8 mg/dL by the
time of starting renal replacement). In the deferred treat-
ment arm, 4 patients died, 18 started renal replacement
(11 of whom had doubled their serum creatinine or had
reached values >8 mg/dL by the time of starting renal
replacement), and 1 had a doubling of serum creatinine
without starting renal replacement. Thus, the difference
between the two arms was largely caused by initiation of
renal replacement. In Kaplan-Meier analyses (Fig. 3), the
difference was formally statistically significant for both
end points (log-rank P = 0.0078 and P = 0.011, respec-
tively). The mean (SD) creatinine clearance in the early
versus deferred EPO arm at the time of initiation of re-
nal replacement was 11.1 (1.5) mL/min versus 11.0 (1.8)
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Fig. 3. Kaplan-Meier plots for doubling of creatinine, renal replace-
ment, or death (A), and renal replacement or death (B) in the early
(thick line) versus deferred (thin line) treatment arms.
mL/min. There was no statistically significant difference
(P = 0.98). The respective mean (SD) serum creatinine
values were 6.69 (0.76) mg/dL and 6.95 (0.85) mg/dL in
the two arms (P = 0.43).
The relative hazard (RH) of doubling of creatinine, re-
nal replacement, or death was 0.42 (95% CI, 0.21–0.83,
P = 0.012) in patients where EPO was started early than
deferred. Adjusting for baseline serum creatinine, the ad-
justed RH was 0.37 (95% CI 0.18–0.73, P = 0.004), while
the risk increased 2.23-fold (95% CI 1.56–3.18, P < 0.001)
per 1 mg/dL higher serum creatinine at baseline. The un-
adjusted RH for death or renal replacement similarly was
0.43 (95% CI 0.22–0.85). Considering both treatment al-
location and initial serum creatinine, the RH was 0.38
(95% CI 0.19–0.76, P = 0.006), while the risk of an event
increased 2.25-fold (95% CI 1.57–3.23, P < 0.001) per
1 mg/dL higher creatinine at baseline. Sex, age, weight,
24-hour protein, creatinine clearance, and the hemato-
logic condition at baseline did not provide any additional
independent information once these two parameters had
been considered for either outcome.
Interaction terms between baseline serum creatinine
and treatment arm were not significant, suggesting a sim-
ilar benefit in patients with high and low baseline crea-
tinine. For doubling of creatinine, renal replacement, or
death, the RH was 0.33 (P = 0.033) in subgroup of pa-
tients with baseline serum creatinine >4 mg/dL (N = 22)
and 0.43 (P = 0.077) for the subgroup of patients with
baseline serum creatinine ≤4 mg/dL (N = 66). The ben-
efit was also similar in subgroups with different baseline
hemoglobin levels [RH 0.38, P = 0.036 for hemoglobin
≥10 g/dL (N = 59) vs. RH 0.44, P = 0.12 for hemoglobin
<10 g/dL (N = 29)], and different levels of baseline pro-
teinuria [RH 0.48, P = 0.13 for proteinuria ≤500 mg per
24 hours (N = 44) vs. RH 0.38, P = 0.054 for proteinuria
>500 mg per 24 hours (N = 44)].
Adverse events
Ten patients were hospitalized, 4 in the early treatment
arm (cardiac disease, pneumonia, urinary tract infections
N = 2) and 6 in the deferred treatment arm (prostate
cancer, pneumonia, cardiac disease, viral infections N =
2, breast cancer). Hypertension was well controlled in
all study subjects. After adjusting for baseline values, the
office measurements of systolic and diastolic, as well as
the mean blood pressure at 12 months were nonsignifi-
cantly higher in the early treatment arm by 1.1 mm Hg
(P = 0.31), 0.3 mm Hg (P = 0.81), and 0.6 mm Hg
(P = 0.59), respectively, and for those patients who had
24-hour determinations the mean blood pressure was
nonsignificantly higher by 0.3 mm Hg (P = 0.87) in the
early EPO arm. One patient in each arm had a mean
blood pressure exceeding 105 mm Hg at baseline in the
office and verified by 24-hour measurements, and 1 other
patient in each arm had a similarly elevated mean blood
pressure at 12 months. Six patients had systolic blood
pressure above 140 mm Hg or diastolic blood pressure
above 90 mm Hg at baseline, but none had such levels at
12 months. No patients developed severe anemia and no
patients had severe allergic reactions to EPO.
DISCUSSION
This randomized controlled trial shows that the initia-
tion of EPO in predialysis patients with non-severe ane-
mia results in a 60% reduction in the risk of initiation of
renal replacement or death. We observed a similar benefit
in patients with different degrees of baseline renal impair-
ment, hemoglobin level, and degree of proteinuria. These
data strongly suggest that early initiation of EPO in pre-
dialysis patients with mild anemia is likely to be highly
beneficial.
Previous randomized trials have clearly documented
the beneficial effect of EPO in predialysis patients to-
ward correcting the anemia of chronic renal failure [1–9].
Various other benefits of raising the hemoglobin to nor-
mal or near normal concentration in the setting of renal
failure, such as improved cognitive function, exercise per-
formance, amelioration of left ventricular performance,
and quality of life have also been reported [9, 24–29].
Some of the randomized studies have already shown that
renal function (as determined by serum creatinine or cre-
atinine clearance and glomerular filtration rate) is not
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deteriorating in the short-term [3, 4], and is probably ac-
tually comparatively better during longer-term follow-up
[5, 7] in patients given EPO versus those not given EPO
treatment. With one exception [7], these studies have not
focused particularly on hard clinical end points. Kyriyama
et al [7] described a significant decrease in the require-
ment for renal replacement in patients treated with in-
travenous EPO in a randomized trial of 73 predialysis
patients. That study recruited patients with more severe
anemia than patients in our study, with a mean hemat-
ocrit of 27.3%, and with all patients having hematocrit
less than 30%. That study also recruited mostly patients
with severe proteinuria (mean 4 g per 24 hours), had a pre-
ponderance of diabetics, and aimed for less strict blood
pressure control (<160/95 mm Hg) than what is the cur-
rent goal. Our study is the first, to our knowledge, to
document a clear clinical benefit for predialysis patients
with mild anemia and strict blood pressure control.
The beneficial effect of predialysis initiation of EPO
in terms of hard clinical outcomes is also supported by
observational data from the Health Care Financing Ad-
ministration [30]. Out of 4866 patients, only 1107 had
started EPO before dialysis. However, these patients had
decreased risk for mortality during follow-up (RH 0.80),
and the benefit was even larger when EPO has resulted in
higher hematocrit (RH 0.67). Recent surveys have shown
that only 11% to 26% of patients initiate EPO before
dialysis and more than two thirds of patients start re-
nal replacement with a hemoglobin <11 mg/dL [14–16].
According to our findings, these surveys reflect inappro-
priate underuse of a beneficial treatment.
In this trial we aimed for hemoglobin levels that are
slightly higher than those recommended by the most re-
cent guidelines [12]. However, the difference is subtle.
The optimal target level for hemoglobin cannot be de-
termined based on our data. The beneficial clinical effect
of EPO could be due to a variety of pathophysiologic
mechanisms. Correcting anemia increases oxygen deliv-
ery to tissues and reduces hypoxia. Hypoxia of tubular
cells may be the main link between interstitial fibrosis
and tubular damage [31]. Chronic reduction in nephron
number is linked with increased oxygen consumption by
the remaining nephrons and increased production of re-
active oxygen species [32]. Oxidative stress may enhance
both tubular damage and interstitial fibrosis. Apoptosis
also plays a role in the progressive loss of tubular cells in
chronic kidney disease [33, 34]. In vitro EPO protects en-
dothelial and vascular smooth muscle cells against apop-
tosis [35, 36]. In theory, other cells that express the EPO
receptor, such as the proximal tubular and medullary col-
lecting duct cells of the kidney [37], could also be pro-
tected against apoptosis.
EPO should be added to the limited list of measures
known to delay end-stage renal disease, including protein
restriction and optimal control of blood pressure [38].
Our study pertains to a nondiabetic population. In dia-
betics, the use of ACEIs is strongly indicated [39] and
recent evidence suggests [40] that ACEIs may offer an
additional benefit beyond that conferred by blood pres-
sure reduction, especially in the presence of considerable
proteinuria, even in nondiabetic patients. This was not as
clear when our study was designed, thus we opted to avoid
angiotensin inhibition because data suggested a potential
interference with response to EPO [17–19], although this
issue is currently controversial [41]. It is possible that if
patients had been treated with ACEIs, the rate of decline
in kidney function might have been somewhat slower in
both groups. Only 3 patients in our study discontinued
angiotensin inhibition therapy in order to be enrolled.
Moreover, the additional benefit of angiotensin inhibi-
tion seems absent among patients with <500 mg daily
urine protein [40]. Our study cohort had generally low
levels of proteinuria, and half of our patients had levels
below 500 mg per 24 hours. Reassuringly, the observed
benefit did not depend on the degree of proteinuria. Nev-
ertheless, our current clinical policy is to use both EPO
and angiotensin inhibition concurrently in patients with
chronic renal disease.
A limitation of the study was the inability to continue
the original design for the anticipated 2 years, although
this did not affect the ability of the trial to show differ-
ences between the compared arms. The form of subcuta-
neous EPO alpha that was used in the trial has currently
been withdrawn because of concerns about PRCA. How-
ever, there is no reason to believe that the other available
forms of EPO would be less beneficial in slowing renal
disease progression. Moreover, it is currently speculated
that the increased incidence of PRCA with the Euro-
pean preparation of subcutaneous EPO alpha compared
with other preparations of subcutaneous EPO is proba-
bly not caused by the drug, but by the replacement of hu-
man serum albumin by polysorbate 80 and glycine in the
preparation. These substances may increase EPO aggre-
gation and enhance antibody formation, and antigenicity
may also be increased by the presence of silicone in pre-
filled syringes [23]. With different preparations of EPO
the rate of PRCA should be too low to be of concern.
We should caution that initiation of renal replace-
ment therapy may be influenced somehow by physician
decision-making in a nonblinded study. Theoretically,
physicians may have attempted to start renal replace-
ment at a more advanced stage of renal failure when pa-
tients had not been randomized to the early EPO arm.
Additionally, if EPO improved overall well being, renal
replacement may have been delayed among EPO recip-
ients, even in the face of very poor renal function. How-
ever, we documented that the renal function at the time of
initiation of renal replacement was very similar in the two
arms. It is also reassuring that the course of serum creati-
nine and creatinine clearance values over time showed a
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clear, statistically significant superiority of the early EPO
arm. Therefore, it is more likely that the delay in initiation
of renal replacement reflects mostly a genuine beneficial
effect of renal disease progression rather than subjective
biases.
CONCLUSION
With these caveats, we conclude that early treatment
of non-severe anemia may be a useful intervention for
deterring the need for renal replacement in patients with
chronic renal failure. A formal cost-effectiveness analysis
could also be performed to evaluate the exact cost-benefit
ratio for the early administration of EPO in such patients.
APPENDIX
The following investigators participated in this multicenter study in
Greece: University Hospital, Ioannina: K. Siamopoulos; Hatzikosta
General Hospital of Ioannina: M. Pappas; Hippocrates Hospi-
tal, Thessalonica: D. Memmos; Evangelismos Hospital, Athens: N.
Nikolopoulou; Laikon General Hospital, Athens: C. Stathakis; Gen-
eral Hospital, Kavala: K. Kalaitzidis; Thriaseion Hospital, Athens: J.
Papadakis; General Hospital, Larissa: I. Stafanidis; Papageorgiou Hos-
pital, Thessalonica: G. Sakellariou; General Hospital, Volos: C. Sirga-
nis; General Hospital, Veria: D. Tsakiris; General Hospital, Edessa:
N. Zoumbaridis; Papanikolaou Hospital, Thessalonica: K. Sombolos;
General Hospital, Kalamata: G. Bristogiannis.
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